Naxitamab is under clinical development by Y-mAbs Therapeutics and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Naxitamab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Naxitamab in Osteosarcoma

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Naxitamab overview

Naxitamab (Danyelza) is a monoclonal antibody, acts as anti-cancer agent. It is formulated as injection solution for intravenous route of administration. Danyelza is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GMCSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. It is also under development for the treatment of ewing sarcoma, metastatic melanoma, triple negative breast cancer, Melanoma.
Naxitamab is under investigation for the treatment of osteosarcoma. It is administered as intravenous infusion. It is a human IgG3 MAb. The drug candidate acts by targeting ganglioside GD2.

Y-mAbs Therapeutics overview

Y-mAbs Therapeutics(Y-mAbs) is a clinical biopharmaceutical company that develops and commercializes novel antibody therapeutic products for cancer treatment. The company technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. Its pipeline products include DANYELZA (naxitamab-gqgk) treats relapsed and refractory high-risk neuroblastoma, front-line induction in high-risk neuroblastoma, relapsed second-line osteosarcoma, chemoimmunotherapy for relapsed and refractory high-risk neuroblastoma; GD2-SADA for solid tumors (SCLC, malignant melanoma, sarcoma);

For a complete picture of Naxitamab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.